Industry Reports

Patent Research and Operational Guide for Daiichi Sankyo's ADC Drug DS-8201(1)

30 August 2024
2 min read

Antibody-Drug Conjugates (ADCs) share a universal tripartite structure consisting of an antibody, linker, and payload. Currently, 272 ADC drugs have been initiated for clinical trials globally. Excluding the market withdrawal of Belantamab mafodotin (Blenrep®), 14 approved ADC products remain available. ADCs, with intricate patent positioning strategies, represent a highly competitive field in pharmaceutical research and development. Taking the Daiichi Sankyo's ADC drug DS-8201 as an example, not only do source patents for each component provide initial protection, but the remarkable pharmacodynamic properties of new combinations significantly aid in patent iteration and extension of market exclusivity periods. When developing new drugs from various existing components, it has become essential for companies to comprehensively and accurately extract and summarize source patent information, core patent information, and iterative patent information for each component of the drug under investigation. This process yields high-quality patent research reports, which are crucial for infringement analysis, biosimilar development, and investment and financing activities. The following guide demonstrates how to conduct detailed patent research for ADC drugs. 

Disclaimer: 

The data presented in this report, primarily sourced from Patsnap Synapse, Bio, Chemical and Analytics databases, may exhibit discrepancies due to data source leakage, variations in statistical periods, and divergent search methodologies. Therefore, it should be regarded as a reference only. This report is not responsible for any business losses resulting from the usage of this information.

Based on the characteristics of ADC drugs, we have summarized the process for conducting patent research on ADC drugs. You can follow the process described below to carry out patent research on ADC drugs.

图示, 文本

描述已自动生成

For more information, please click the image link below to access the full report.

图形用户界面, 网站

描述已自动生成

EU Commission Approves RYBREVANT® (Amivantamab) with Chemotherapy for Treatment-Resistant Advanced EGFR-Mutated NSCLC in Adults
Latest Hotspot
4 min read
EU Commission Approves RYBREVANT® (Amivantamab) with Chemotherapy for Treatment-Resistant Advanced EGFR-Mutated NSCLC in Adults
30 August 2024
The European Commission greenlights RYBREVANT®▼ (amivantamab) alongside chemotherapy for adults with advanced EGFR-mutated NSCLC after previous treatments haven't worked.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Aug 30
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Aug 30
30 August 2024
Aug 30th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Tonix Pharmaceuticals and Bilthoven Biologicals Collaborate to Develop TNX-801 Mpox Vaccine
Latest Hotspot
3 min read
Tonix Pharmaceuticals and Bilthoven Biologicals Collaborate to Develop TNX-801 Mpox Vaccine
29 August 2024
Tonix Pharmaceuticals partners with Bilthoven Biologicals to advance TNX-801 Mpox vaccine development.
Read →
siRNA Drug Amvuttra Patent Research and Practical Operation Guide(3)
siRNA Drug Amvuttra Patent Research and Practical Operation Guide(3)
29 August 2024
Based on the characteristics of siRNA drugs, we have summarized the process for conducting patent research on siRNA drugs.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.